Price (delayed)
$0.25
Market cap
$14.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.78
Enterprise value
-$3.53M
Highlights
Elevation Oncology's quick ratio has increased by 20% QoQ and by 4% YoY
The EPS has increased by 38% year-on-year but it has declined by 5% since the previous quarter
ELEV's equity is down by 13% since the previous quarter but it is up by 10% year-on-year
The debt has grown by 3.3% YoY
Key stats
What are the main financial stats of ELEV
MarketValuationsEarnings
Shares outstanding
59.22M
Market cap
$14.8M
Enterprise value
-$3.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$44.7M
Net income
-$44.49M
EBIT
-$43.24M
EBITDA
-$43.22M
Free cash flow
-$36.36M
Per shareBalance sheetLiquidity
EPS
-$0.78
EPS diluted
-$0.78
Free cash flow per share
-$0.63
Book value per share
$1.02
Revenue per share
$0
TBVPS
$1.67
Total assets
$95.63M
Total liabilities
$35.6M
Debt
$31.13M
Equity
$60.03M
Working capital
$90.26M
Debt to equity
0.52
Current ratio
21.21
Quick ratio
20.86
Net debt/EBITDA
0.42
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41.8%
Return on equity
-62.2%
Return on invested capital
-60.4%
Return on capital employed
-47.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELEV stock price
How has the Elevation Oncology stock price performed over time
Intraday
-3.29%
1 week
-3.85%
1 month
-48.59%
1 year
-95.06%
YTD
-55.56%
QTD
-3.51%
Financial performance
How have Elevation Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.7M
Net income
-$44.49M
Gross margin
N/A
Net margin
N/A
ELEV financials
Elevation Oncology's operating income has decreased by 6% QoQ
ELEV's net income is down by 6% QoQ but it is up by 2.7% YoY
Growth
What is Elevation Oncology's growth rate over time
ELEV growth chart
Valuation
What is Elevation Oncology stock price valuation
P/E
N/A
P/B
0.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has increased by 38% year-on-year but it has declined by 5% since the previous quarter
Price to book (P/B)
ELEV's P/B is 83% below its last 4 quarters average of 1.5
ELEV's equity is down by 13% since the previous quarter but it is up by 10% year-on-year
Price to sales (P/S)
Efficiency
How efficient is Elevation Oncology business performance
ELEV's ROIC is up by 36% YoY but it is down by 2.5% QoQ
The return on equity rose by 24% year-on-year but it has declined by 4.2% since the previous quarter
Elevation Oncology's ROA has increased by 14% YoY but it has decreased by 4.2% from the previous quarter
Dividends
What is ELEV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELEV.
Financial health
How did Elevation Oncology financials performed over time
Assets vs liabilities
The total assets is 169% greater than the total liabilities
Elevation Oncology's quick ratio has increased by 20% QoQ and by 4% YoY
Elevation Oncology's current ratio has increased by 19% from the previous quarter
Debt vs equity
The debt is 48% less than the equity
The debt to equity has grown by 16% from the previous quarter but it has contracted by 5% YoY
ELEV's equity is down by 13% since the previous quarter but it is up by 10% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.